Nabriva Therapeutics (NASDAQ:NBRV) Stock Price Passes Below 50-Day Moving Average of $1.89
Nabriva Therapeutics (NASDAQ:NBRV) Stock Price Passes Below 50-Day Moving Average of $1.89
Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.89 and traded as low as $1.50. Nabriva Therapeutics shares last traded at $1.51, with a volume of 19,485 shares trading hands.
納布里瓦治療有限公司（NASDAQ：NBRV-獲取評級）股票在周二交易期間低於其五十天移動平均線通過。該股票的五十天移動平均線為 1.89 美元，交易價格低至 1.50 美元。納布里瓦治療學股票的最後交易價格為 1.51 美元，交易量為 19,485 股。
Analyst Upgrades and Downgrades
分析師升級和降級
Several brokerages recently weighed in on NBRV. Northland Securities lowered shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a research report on Friday, January 6th. StockNews.com started coverage on Nabriva Therapeutics in a report on Wednesday. They set a "hold" rating on the stock.
幾家經紀公司最近對 NBRV 進行了權衡。北國證券在 1 月 6 日（星期五）的一份研究報告中將 Nabriva 治療學的股票從「跑贏大市」評級降至「表現不佳」評級。Stocknews.com 在周三的一份報告中開始報導納布里瓦治療學。他們設置了股票的「持有」評級。
Nabriva Therapeutics Stock Performance
納布里瓦治療學股票表現
The company has a debt-to-equity ratio of 0.02, a current ratio of 2.20 and a quick ratio of 1.40. The firm has a fifty day simple moving average of $1.89 and a 200 day simple moving average of $3.61. The company has a market cap of $46.26 million, a price-to-earnings ratio of -0.08 and a beta of 1.67.
該公司的債務與權益比率為 0.02，流動比率為 2.20，快速比率為 1.40。該公司有一個五十天的簡單移動平均線 1.89 美元和 200 天的簡單移動平均線 3.61 美元。該公司的市值為 4,626 萬美元，股價與收益比率為 -0.08，測試版為 1.67。
Hedge Funds Weigh In On Nabriva Therapeutics
對沖基金權衡納布里瓦治療
A hedge fund recently raised its stake in Nabriva Therapeutics stock. Renaissance Technologies LLC lifted its stake in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after acquiring an additional 402,144 shares during the period. Renaissance Technologies LLC owned approximately 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.23% of the company's stock.
一家對沖基金最近籌集了其在 Nabriva 治療學股份的股份。根據該公司最近向證券交易委員會提交的 13F 表格中，文藝復興技術有限公司在第二季度將其在納布里瓦治療學公司（NASDAQ：NBRV-獲得評級）的股份取消了 102.1％。在期內，該基金擁有該生物科技公司股票 795,938 股股份後，再收購 402,144 股股份。文藝復興技術有限責任公司擁有約 0.13% 納布里瓦治療的價值 $145,000 在最近的報告期結束.機構投資者和對沖基金擁有公司股票的 0.23%。
About Nabriva Therapeutics
關於納布里瓦治療
(Get Rating)
(取得評分)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Nabriva Theraptics Plc 是一家生物製藥公司，致力於治療嚴重感染的新型抗感染藥物的研究，開發和商業化。其產品管線包括利福霉素、聯盟和 BC-7013。該公司成立於 2005 年 10 月，總部位於愛爾蘭都柏林。
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab's First U.S. Launch Send Stock Into Stratosphere?
- When Will Crane Holdings Take Flight?
- 獲取有關納布里瓦治療學（NBRV）的研究報告的免費副本
- 普利安特治療學缺口 34％ 更高：更多的上升空間來？
- 2023 年初裁員將如何影響這 5 種生物技術股票？
- 在 70％ 的峰值之後，鮑達斯生物投資者的痛苦是否已經過去？
- 火箭實驗室的第一次美國發射會將股票送入平流層嗎？
- 起重機控股何時起重機飛行？
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每日接收納布里瓦治療學的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Nabriva 治療及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。